Episode 138. Emotional Intelligence with Shawn Price
Emotional intelligence (EI) also known as EQ, is the ability to perceive, understand and manage emotions in positive ways to communicate effectively, empathise with others, overcome challenges and defuse conflict as well as to relieve stress. Emotional intelligence helps build stronger relationships, achieve personal career goals, and interact more positively at work. It gives us an ability to join intelligence, empathy, and emotions to enhance thought and understanding of interpersonal dynamics, guiding our thinking and behaviour. For as in Shakespeare’s Hamlet - 'there is nothing either good nor bad but thinking makes it so'.
Emotional intelligence (EI) also known as EQ, is the ability to perceive, understand and manage emotions in positive ways to communicate effectively, empathise with others, overcome challenges and defuse conflict as well as to relieve stress. Emotional intelligence helps build stronger relationships, achieve personal career goals, and interact more positively at work. It gives us an ability to join intelligence, empathy, and emotions to enhance thought and understanding of interpersonal dynamics, guiding our thinking and behaviour. For as in Shakespeare’s Hamlet - 'there is nothing either good nor bad but thinking makes it so'.
The term EI first appeared in writing in 1964 and was popularised by Daniel Goleman in his book titled Emotional Intelligence published in 1995 in which he applied the concept especially to business defining the term as an array of skills and characteristics that drive leadership and performance. EI is commonly defined by four domains or attributes including:
1. Self-Awareness-Understanding what you are feeling and why and appreciating your strengths and weaknesses.
2. Self-Management- The ability to control impulsive feelings and behaviours, adapt to changing circumstances and manage emotions in healthy ways. This is also referred to as self-regulation and points to a positive outlook and achievement.
3. Social awareness -Including the concept of empathy which helps us understand the emotions, needs and concerns of others. Developing social awareness allows us to recognise the power dynamics in a group or organisation.
4. Relationship management-Which encompasses conflict management, coaching and mentorship and encourages the development of teamwork through inspirational leadership.
There are several excellent books on the subject of emotional intelligence including: Achieving Emotional Literacy by Claude Steiner,
'How Emotions are Made' by Lisa Feldman Barrett, Emotional Agility by Susan David and Daniel Goleman’s Emotional Intelligence.
I was curious to explore this topic in more detail and was privileged recently to meet Shawn Price who is an expert in this field.
Shawn initially trained as a mathematician but was drawn to the study of psychology and especially emotional intelligence recognising its important application to both business, families, and individuals.
Shawn now manages his company Positive Intelligence from where he coaches and consults privately as well as being engaged by industry and large organisations to run workshops and lecture programs on this important subject. Please welcome Shawn to the podcast.
References: Shawn Price: Positive Intelligence. www.positiveintelligence.com.au
Emotional Intelligence, Daniel Goleman.
ISBN:9780553804911 Emotional Intelligence;
www.helpguide.org/ Segal, Robinson and Shubin Emotional Intelligence has 12 Elements.
Which do you need to work on? Harvard Business Review. Feb 06,2017. Goleman and Boyatzis
Episode 47. Helicobacter Pylori with Dr Darcy Holt
Helicobacter pylori is a gram-negative curved bacillus that may colonise the gastric and proximal duodenal mucosa. Its significance was first described by Barry Marshall and Robin Warren in 1982 both of whom were awarded the Nobel prize in 2005 after the Nobel community described the discovery as the most impacting in medical sciences. Most medical practitioners are aware of the pathophysiological consequences of Helicobacter which is responsible for gastritis, gastric and duodenal ulcer disease, and may be associated with gastric adenocarcinoma as well as mucosa associated lymphoid tissue hyperplasia (MALT lymphoma). Its eradication has largely hinged on standard triple therapy including a PPI combined with amoxicillin and clarithromycin taken together for 1 week in Australia; unfortunately this regimen has a 10-15% failure rate.
Helicobacter pylori is a gram-negative curved bacillus that may colonise the gastric and proximal duodenal mucosa. Its significance was first described by Barry Marshall and Robin Warren in 1982 both of whom were awarded the Nobel prize in 2005 after the Nobel community described the discovery as the most impacting in medical sciences. Most medical practitioners are aware of the pathophysiological consequences of Helicobacter which is responsible for gastritis, gastric and duodenal ulcer disease, and may be associated with gastric adenocarcinoma as well as mucosa associated lymphoid tissue hyperplasia (MALT lymphoma). Its eradication has largely hinged on standard triple therapy including a PPI combined with amoxicillin and clarithromycin taken together for 1 week in Australia; unfortunately this regimen has a 10-15% failure rate.
In this episode we are joined today by Dr Darcy Holt, an experienced gastroenterologist to discuss second line treatments that may be considered when first line triple therapy fails.
Darcy covers:
· Current Australian antibiotic guidelines
· Alternate quadruple therapies that are effective in eradication although not subsidised by the PBS at this time
There is a large body of information we cover in this interesting episode, please join me and Darcy.
Maastricht V/Florence Consensus Report recommends:
o Bismuth quadruple therapy for 10-14 days including bismuth subcitrate 120mg qid, tetracycline 500mg qid, metronidazole 400mg tds and PPI bd
o Fluoroquinolone (levofloxacin) 500mg daily, Amoxicillin 1g bd plus PPI standard dose bd (can be converted to quadruple by adding Bismuth 120mg qid or 240mg bd for 10-14 days
o PPI 40mg bd, Bismuth 120mg qid, Tetracycline 500mg qid, Levofloxacin 500mg daily for 10 days (98% effective)
o PPI standard dose qid plus Amoxicillin 750mg bd 14 days – 89% effective
Useful references include:
- www.mja.com.au (MJA 2016:204, 376-380)
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.
Episode 9. Gastro-Oesophageal Reflux Disease with Dr Puneet Mahindra
In this episode I interview experienced gastroenterologist Dr Puneet Mahindra on the common clinical problem of gastro-oesophageal reflux disease. Puneet details - · Risk factors · Complications · Approaches to management He provides personal tips drawn from experience and the literature outlining an approach that should be helpful to everyone practicing clinical medicine.
In this episode I interview experienced gastroenterologist Dr Puneet Mahindra on the common clinical problem of gastro-oesophageal reflux disease. Puneet details –
· Risk factors
· Complications
· Approaches to management
He provides personal tips drawn from experience and the literature outlining an approach that should be helpful to everyone practicing clinical medicine.
Puneet also walks us through his journey to becoming a gastroenterologist, growing up in India, working and studying in the United Kingdom and then Australia. I hope you enjoy the conversation.
Useful references include –
www.gesa.org.au (Clinical update and Management guidelines)
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.
Episode 4. Hepatitis C with Dr Ferry Rusli
In this episode I have a conversation with hepatologist and gastroenterologist Dr Ferry Rusli in a four-part series on liver disease where we explore chronic hepatitis C, its population reservoirs in Australia and approaches to treatment. In particular, Ferry points out - · The need to increase our effectiveness at treating hepatitis C in at risk populations.
In this episode I have a conversation with hepatologist and gastroenterologist Dr Ferry Rusli in a four-part series on liver disease where we explore chronic hepatitis C, its population reservoirs in Australia and approaches to treatment. In particular, Ferry points out - · The need to increase our effectiveness at treating hepatitis C in at risk populations.
In this episode I have a conversation with hepatologist and gastroenterologist Dr Ferry Rusli in a four-part series on liver disease where we explore chronic hepatitis C, its population reservoirs in Australia and approaches to treatment.
In particular, Ferry points out –
· The need to increase our effectiveness at treating hepatitis C in at risk populations (e.g. prison population)
· Discusses the impressive breakthrough with new antiviral therapies and their effectiveness in curing hepatitis C
· Surveillance for hepatocellular carcinoma
I really hope you find this conversation as interesting as I did.
Useful references include -
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.
Episode 3. Hepatitis B with Dr Ferry Rusli
In this episode I talk with experienced gastroenterologist and hepatologist Dr Ferry Rusli on the subject of hepatitis B in a four-part series on liver disease. Ferry discusses - · the prevalence of hepatitis B in the Asia Pacific region · the long-term complications and consequences of hepatitis B · treatment options including pharmacological therapies which are currently falling short of the national target for patients receiving treatment.
In this episode I talk with experienced gastroenterologist and hepatologist Dr Ferry Rusli on the subject of hepatitis B in a four-part series on liver disease. Ferry discusses -
· the prevalence of hepatitis B in the Asia Pacific region
· the long-term complications and consequences of hepatitis B
· treatment options including pharmacological therapies which are currently falling short of the national target for patients receiving treatment.
This conversation provides a great introduction to current approaches to hepatitis B management. I hope you enjoy the conversation.
Useful reference are -
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.
Episode 2. Non-Alcoholic Fatty Liver Disease with Dr Ferry Rusli
In this episode I am joined by Dr Ferry Rusli, an experienced gastroenterologist and hepatologist to discuss non-alcoholic fatty liver disease in a four-part series on hepatology. Ferry discusses the relevance of non-alcoholic fatty liver disease to the metabolic syndrome and some key management points, in particular focussing on controlling body mass index. There is much to learn from this conversation with Ferry, I hope you enjoy the conversation.
In this episode I am joined by Dr Ferry Rusli, an experienced gastroenterologist and hepatologist to discuss non-alcoholic fatty liver disease in a four-part series on hepatology.
Ferry discusses –
· the prevalence of non-alcoholic fatty liver disease (NAFLD) as it applies to the Australian population
· non-alcoholic steatohepatitis (NASH)
· cirrhosis, hepatocellular carcinoma and liver failure as sequela of unmanaged NASH
Ferry discusses the relevance of non-alcoholic fatty liver disease to the metabolic syndrome and some key management points, in particular focussing on controlling body mass index. There is much to learn from this conversation with Ferry, I hope you enjoy the conversation.
Useful references include -
www.hepvic.org.au/fattyliverdisease
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.
Episode 1. Abnormal Liver functions with Dr Ferry Rusli
In this episode I interview gastroenterologist and hepatologist Dr Ferry Rusli in the first of a four-part series on liver disease. Ferry discusses his approach to a patient presenting with abnormal liver function tests and navigates us through - · Obstructive liver patterns · Hepatitic patterns Ferry will address in broad terms common aetiologies such as non-alcoholic fatty liver disease, chronic hepatitides, acute viral infections, biliary obstruction, malignancy and the possibility of drug side-effects.
In this episode I interview gastroenterologist and hepatologist Dr Ferry Rusli in the first of a four-part series on liver disease. Ferry discusses his approach to a patient presenting with abnormal liver function tests and navigates us through -
· Obstructive liver patterns
· Hepatitic patterns
Ferry will address in broad terms common aetiologies such as non-alcoholic fatty liver disease, chronic hepatitides, acute viral infections, biliary obstruction, malignancy and the possibility of drug side-effects. There are some great insights to be gained here. We also find out about Ferry’s journey into medicine growing up in Indonesia, completing schooling in Melbourne and being awarded the travel scholarship in hepatology from the Gastroenterological Society of Australia. I hope you enjoy the show.
Useful reference -
www.gihealth.com.au
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.